866-997-4948(US-Canada Toll Free)

Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast-2025

Published By :

DelveInsight

Published Date : Sep 2017

Category :

N/A

No. of Pages : 70 Pages

DelveInsights Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast-Market Insights, Epidemiology and Market Forecast-2025 report provides an overview of the disease and in depth research related to Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.

This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast. It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast for 7 major markets. The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast market, as well as treatment algorithm, current treatments & advancements are included.
The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast, providing an in-depth analysis of emerging therapies which will create an impact through their launch.
According to DelveInsight, the forecasted patient population of Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast 7MM market size is estimated to be USD XX by 2025. The DelveInsight Report will help in enhanced understanding of the Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast market from inside out, with transparency into the calculated patient forecasting data and estimated market size.
Key Coverage
Understanding historical and forecasted epidemiological data for Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast covering 7MM from 2015-2025.
Segment level epidemiology and market split for Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast.
The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast.
The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast market trends.
Thorough market distribution based on market share for Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast.
Reasons to buy:
The report will help in developing business strategies by understanding trends shaping and driving the Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast market.
To understand the future market competition in the Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast market and Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology and Market Forecast in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
1. Report Introduction
2. Age-related Macular Degeneration (AMD) Market Overview at a Glance
2.1. Total Market Share Distribution of Age-related Macular Degeneration (AMD) for 7 MM in 2016
2.2. Total Market Share Distribution of Age-related Macular Degeneration (AMD) for 7 MM in 2025
3. Age-related Macular Degeneration (AMD)
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment
4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Age-related Macular Degeneration (AMD) in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Age-related Macular Degeneration (AMD) in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Age-related Macular Degeneration (AMD) in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Age-related Macular Degeneration (AMD) in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Age-related Macular Degeneration (AMD) in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Age-related Macular Degeneration (AMD) in United Kingdom
5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices
6. Marketed Drugs for Age-related Macular Degeneration (AMD)
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status
7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase
8. Overview of Total Age-related Macular Degeneration (AMD) Market (2016 & 2025)
9. Age-related Macular Degeneration (AMD): Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)
10. Market Drivers
11. Market Restraints
12. Appendix
13. Report Methodology
14. Consulting Services
15. Disclaimer
16. About DelveInsight


List of Tables

Table 1: Diagnosed Cases Age-related Macular Degeneration (AMD) in United States (2015-2025)
Table 2: Diagnosed Cases Age-related Macular Degeneration (AMD) in Germany (2015-2025)
Table 3: Diagnosed Cases Age-related Macular Degeneration (AMD) in France (2015-2025)
Table 4: Diagnosed Cases Age-related Macular Degeneration (AMD) in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Age-related Macular Degeneration (AMD) in Spain (2015-2025)
Table 6: Diagnosed Cases Age-related Macular Degeneration (AMD) in Italy (2015-2025)
Table 7: Diagnosed Cases Age-related Macular Degeneration (AMD) in Japan (2015-2025)
Table 8: List of Marketed Drugs for Age-related Macular Degeneration (AMD)
Table 9: List of Pipeline Phase III Drugs for Age-related Macular Degeneration (AMD)
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 17: Germany Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 18: France Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 20: Spain Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 21: Italy Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 22: Japan Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)

List of Figures
Figure 1: Diagnosed Cases Age-related Macular Degeneration (AMD) in United States (2015-2025)
Figure 2: Diagnosed Cases Age-related Macular Degeneration (AMD) in Germany (2015-2025)
Figure 3: Diagnosed Cases Age-related Macular Degeneration (AMD) in France (2015-2025)
Figure 4: Diagnosed Cases Age-related Macular Degeneration (AMD) in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Age-related Macular Degeneration (AMD) in Spain (2015-2025)
Figure 6: Diagnosed Cases Age-related Macular Degeneration (AMD) in Italy (2015-2025)
Figure 7: Diagnosed Cases Age-related Macular Degeneration (AMD) in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Age-related Macular Degeneration (AMD)
Figure 9: List of Pipeline Phase III Drugs for Age-related Macular Degeneration (AMD)
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 17: Germany Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 18: France Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 20: Spain Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 21: Italy Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 22: Japan Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Age-related Macular Degeneration (AMD) Market (7MM)
Age-related Macular Degeneration (AMD) Market forecasting
Age-related Macular Degeneration (AMD) Sales forecasting
Age-related Macular Degeneration (AMD) Market segments
Age-related Macular Degeneration (AMD) Epidemiology
Age-related Macular Degeneration (AMD) Pipeline products and technologies
Age-related Macular Degeneration (AMD) Competitive landscape
Age-related Macular Degeneration (AMD) SWOT analysis
Age-related Macular Degeneration (AMD) Market Drivers and barriers
Age-related Macular Degeneration (AMD) Key Companies and Funding

List of Table

Table 1: Diagnosed Cases Age-related Macular Degeneration (AMD) in United States (2015-2025)
Table 2: Diagnosed Cases Age-related Macular Degeneration (AMD) in Germany (2015-2025)
Table 3: Diagnosed Cases Age-related Macular Degeneration (AMD) in France (2015-2025)
Table 4: Diagnosed Cases Age-related Macular Degeneration (AMD) in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Age-related Macular Degeneration (AMD) in Spain (2015-2025)
Table 6: Diagnosed Cases Age-related Macular Degeneration (AMD) in Italy (2015-2025)
Table 7: Diagnosed Cases Age-related Macular Degeneration (AMD) in Japan (2015-2025)
Table 8: List of Marketed Drugs for Age-related Macular Degeneration (AMD)
Table 9: List of Pipeline Phase III Drugs for Age-related Macular Degeneration (AMD)
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 17: Germany Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 18: France Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 20: Spain Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 21: Italy Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Table 22: Japan Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)

List of Chart

Figure 1: Diagnosed Cases Age-related Macular Degeneration (AMD) in United States (2015-2025)
Figure 2: Diagnosed Cases Age-related Macular Degeneration (AMD) in Germany (2015-2025)
Figure 3: Diagnosed Cases Age-related Macular Degeneration (AMD) in France (2015-2025)
Figure 4: Diagnosed Cases Age-related Macular Degeneration (AMD) in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Age-related Macular Degeneration (AMD) in Spain (2015-2025)
Figure 6: Diagnosed Cases Age-related Macular Degeneration (AMD) in Italy (2015-2025)
Figure 7: Diagnosed Cases Age-related Macular Degeneration (AMD) in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Age-related Macular Degeneration (AMD)
Figure 9: List of Pipeline Phase III Drugs for Age-related Macular Degeneration (AMD)
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 17: Germany Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 18: France Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 20: Spain Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 21: Italy Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)
Figure 22: Japan Market Size of Age-related Macular Degeneration (AMD) in USD, Million (2015-2025)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *